Healthcare · NSE: PARKHOSPS
Park Medi World
Q2 FY27 earnings highlights, from the results presentation
Q2 FY27 · From the investor presentation
- M.Cap
- ₹10,584Cr
- P/E
- 41.3×
- 1Y return
- —
- From 52W high
- −19.7%
Highlights are read by AI from the company's filing and can contain mistakes. Check the source page linked to each line.
Share price
Results Q2 FY27, as filed · consolidated · ₹ Cr
| Q2 FY27 | Year ago | YoY | Q1 FY27 | QoQ | |
|---|---|---|---|---|---|
| Revenue | 511 | — | — | 476 | +7.4% |
| EBITDA | 102 | — | — | 126 | -19.3% |
| EBITDA margin | 19.9% | — | — | 26.5% | -660 bps |
| PBTProfit before tax | 76 | — | — | 105 | -27.3% |
| Net profit | 52 | — | — | 83 | -36.7% |
| EPS (₹) | 1.26 | — | — | 2.05 | -38.5% |
From the company's own results filing on NSE. Net profit is the owners' share. Growth and the dotted lines are worked out from the filed figures.
More figures from the presentation
“we added 680 beds in just six months through Rudrapur and Panchkula,”
“3,890 Expansion / +100 (225 → 325) / Q4 FY’27”
“Acquisition – O&M / 300 / Q4 FY’27”
“Acquisition / 200 / Q4 FY’27”
“Acquisition / 150 / Dec 2026”
“Acquisition - O&M / 400 / Apr 2027”
In short
- 01H1 FY27 revenue was INR 9,867 mn, up 22% YoY; Q2 revenue was INR 5,110 mn, up 25%.
- 02Q2 EBITDA fell 10% to INR 1,017 mn and net profit fell 31% to INR 545 mn; EBITDA margin was 20% vs 27%.
- 03Management said new capacity had a near-term bearing on occupancy and profitability.
- 04H1 FY27 margins for the 14 hospitals other than Agra, Panchkula and Rudrapur were 26% EBITDA and 17% net.
- 05The company expects 1,430 bed additions in FY27, reaching 5,040 beds by March 2027.
- 06Bed capacity is planned to rise c.83% by Dec 2028, to 6,590 beds, funded by internal accruals and debt.
- 07Cash was INR 3,713 mn against term debt of INR 1,779 mn.
Capex
Fixed assets INR 10,987 mn at H1 FY27 vs 7,878 mn at FY26
Slides · p. 25
Fixed assets INR 10,987 mn at H1 FY27 vs 7,878 mn at FY26
“Reserves 20,728 19,356 Fixed assets 10,987 7,878”
Capacity
Mohali: Mohali expansion +150 beds (350 to 500), Sep 2027
Slides · p. 19
Mohali: Mohali expansion +150 beds (350 to 500), Sep 2027
“Expansion / +150 (350 → 500) / Sep 2027”
Ambala: Ambala expansion +200 beds (250 to 450), Oct 2027
Slides · p. 19
Ambala: Ambala expansion +200 beds (250 to 450), Oct 2027
“Expansion / +200 (250 → 450) / Oct 2027”
Rohtak: Rohtak greenfield, 250 beds, Jan 2028
Slides · p. 19
Rohtak: Rohtak greenfield, 250 beds, Jan 2028
“Greenfield / 250 / Jan 2028”
Prayagraj: Prayagraj greenfield on lease, 550 beds, Dec 2028
Slides · p. 19
Prayagraj: Prayagraj greenfield on lease, 550 beds, Dec 2028
“Greenfield - Lease / 550 / Dec 2028”
Network of 17 hospitals and 4,290 beds across North India
Slides · p. 9
Network of 17 hospitals and 4,290 beds across North India
“17 hospitals and 4,290 beds across North India”
Demand
North India: North India market share expected to grow the fastest
Slides · p. 22
North India: North India market share expected to grow the fastest
“Market share of North India expected to grow the fastest”
North India: North India bed density below India and global averages, a supply gap
Slides · p. 22
North India: North India bed density below India and global averages, a supply gap
“• North India on average remains below both levels, indicating a significant supply gap”
Growing focus on international patients and premium case mix
Slides · p. 20
Growing focus on international patients and premium case mix
“• Growing focus on international patients and premium case mix”
About 10-15% rate increase shown under CGHS rate revision
Slides · p. 23
About 10-15% rate increase shown under CGHS rate revision
“~10–15% rate increase Coverage in (Mn)”
About 3 mn beds required in India to bridge demand-supply gap
Slides · p. 22
About 3 mn beds required in India to bridge demand-supply gap
“~3 Mn beds required”
Margins and costs
Q2 FY27 EBITDA INR 1,017 mn vs 1,127 mn, down 10%; H1 EBITDA up 5% to 2,278 mn
Slides · p. 26
Q2 FY27 EBITDA INR 1,017 mn vs 1,127 mn, down 10%; H1 EBITDA up 5% to 2,278 mn
“EBITDA 1,017 1,127 -10% 2,278 2,177 5%”
Q2 FY27 EBITDA margin 20% vs 27%, down 758 bps; H1 margin 23% vs 27%
Slides · p. 26
Q2 FY27 EBITDA margin 20% vs 27%, down 758 bps; H1 margin 23% vs 27%
“EBITDA Margin (%) 20% 27% -758 bps 23% 27% -382 bps”
Q2 cost of material/services up 65% to INR 1,163 mn
Slides · p. 26
Q2 cost of material/services up 65% to INR 1,163 mn
“Cost of material consumed /services rendered 1,163 705 65% 1,926 1,405 37%”
14 hospitals other than Agra, Panchkula and Rudrapur: H1 FY27 margins for 14 older hospitals: EBITDA 26%, net profit 17%
Slides · p. 26
14 hospitals other than Agra, Panchkula and Rudrapur: H1 FY27 margins for 14 older hospitals: EBITDA 26%, net profit 17%
“(1) H1 FY’27 EBITDA margin and Net Profit margin for 14 hospitals other than Agra, Panchkula and Rudrapur (additions in the current CY) were 26% and 17%”
Q2 depreciation up 40% to INR 209 mn
Slides · p. 26
Q2 depreciation up 40% to INR 209 mn
“Depreciation 209 149 40% 397 297 34%”
Debt and working capital
Cash of INR 3,713 mn against term debt of INR 1,779 mn
Slides · p. 6
Cash of INR 3,713 mn against term debt of INR 1,779 mn
“utilisation and margins. With cash of INR 3,713 mn against term debt of INR 1,779 mn, we have the balance sheet strength”
Fixed deposits of INR 2,950 mn
Slides · p. 20
Fixed deposits of INR 2,950 mn
“• Strong liquidity with ₹2,950 mn in FDs”
Non-current borrowings INR 1,779 mn at H1 FY27 vs 190 mn at FY26
Slides · p. 25
Non-current borrowings INR 1,779 mn at H1 FY27 vs 190 mn at FY26
“Non-Current Borrowings 1,779 190 Other Intangible Assets 12 12”
Current borrowings INR 2,792 mn at H1 FY27 vs 2,089 mn at FY26
Slides · p. 25
Current borrowings INR 2,792 mn at H1 FY27 vs 2,089 mn at FY26
“Current Borrowings 2,792 2,089 Current Assets”
Trade receivables INR 8,710 mn at H1 FY27 vs 5,935 mn at FY26
Slides · p. 25
Trade receivables INR 8,710 mn at H1 FY27 vs 5,935 mn at FY26
“Trade Payables 678 1,090 Trade receivables 8,710 5,935”
Fund raising
Mix of internal accruals and debt to fund scale-up to 6,590 beds
Slides · p. 20
Mix of internal accruals and debt to fund scale-up to 6,590 beds
“• Mix of Internal accruals and debt to scale up to 6,590”
Promoter holding at ~82.9%
Slides · p. 20
Promoter holding at ~82.9%
“• Promoter holding at ~82.9%”
Headroom for equity dilution up to regulatory threshold of ~75%
Slides · p. 20
Headroom for equity dilution up to regulatory threshold of ~75%
“• Headroom for dilution up to regulatory threshold (~75%)”
Flexibility for a future equity raise if required
Slides · p. 20
Flexibility for a future equity raise if required
“• Provides flexibility for future equity raise if required”
Headroom to raise debt for future growth
Slides · p. 20
Headroom to raise debt for future growth
“• Significant headroom to raise debt for future growth”
Acquisitions and new business
Capacity to raise capital for unidentified acquisitions
Slides · p. 20
Capacity to raise capital for unidentified acquisitions
“• Additional capacity to raise capital for unidentified”
Rudrapur: The Medicity, Rudrapur, 330 beds, operational since Aug 2026
Slides · p. 2
Rudrapur: The Medicity, Rudrapur, 330 beds, operational since Aug 2026
“The Medicity, Rudrapur | 330 beds, Operational since Aug 2026”
Rudrapur: Multi super speciality hospital acquired for Rs 177 Cr (The Medicity, Rudrapur)
Slides · p. 18
Rudrapur: Multi super speciality hospital acquired for Rs 177 Cr (The Medicity, Rudrapur)
“• Multi super speciality for ₹177 Cr; NABH”
Zirakpur: Hospital acquired for about Rs 107 Cr (Mehar Hospital, Zirakpur column)
Slides · p. 18
Zirakpur: Hospital acquired for about Rs 107 Cr (Mehar Hospital, Zirakpur column)
“• Acquired for ~₹107 Cr • Gurugram cluster to”
Risks
New capacity had a near-term bearing on occupancy and profitability
Slides · p. 6
New capacity had a near-term bearing on occupancy and profitability
“As expected, onboarding this new capacity has had a near-term bearing on occupancy and profitability, as new”
Other
H1 FY27 revenue was INR 9,867 mn, up 22% YoY, highest-ever half-year
Slides · p. 6
H1 FY27 revenue was INR 9,867 mn, up 22% YoY, highest-ever half-year
“delivered our highest-ever half-yearly Revenue of INR 9,867 mn, up 22% YoY, with Q2 Revenue rising”
Q2 FY27 revenue INR 5,110 mn vs 4,102 mn, up 25%; H1 INR 9,867 mn, up 22%
Slides · p. 26
Q2 FY27 revenue INR 5,110 mn vs 4,102 mn, up 25%; H1 INR 9,867 mn, up 22%
“Revenue (ex Other income) 5,110 4,102 25% 9,867 8,090 22%”
Q2 FY27 net profit INR 545 mn vs 787 mn, down 31%; H1 down 1% to 1,431 mn
Slides · p. 26
Q2 FY27 net profit INR 545 mn vs 787 mn, down 31%; H1 down 1% to 1,431 mn
“Net Profit 545 787 -31% 1,431 1,442 -1%”
Q2 FY27 EPS INR 1.26 vs 2.05, down 38%; H1 EPS INR 3.31 vs 3.75
Slides · p. 26
Q2 FY27 EPS INR 1.26 vs 2.05, down 38%; H1 EPS INR 3.31 vs 3.75
“EPS (INR) 1.26 2.05 -38% 3.31 3.75 -12%”
Priorities: integrating new assets, improving utilisation and margins
Slides · p. 6
Priorities: integrating new assets, improving utilisation and margins
“capacity and the largest addition in our history. Our priorities now are the seamless integration of these assets, improving”
Sources
- Investor presentation, Q2 FY27 Filed 13 Nov 2026 · 28 pages
Management's own statements, quoted from its NSE filings. This page was read by AI and can contain mistakes: check the source pages before relying on any figure. No forecast or opinion of ours. Not investment advice.

